Full Press Release Details
Forward Looking Statements
presentation contains certain "forward-looking statements" within the meaning
the Private Securities Litigation Reform Act of 1995, as amended. Such
statements may include statements regarding the efficacy and intended use
Nephros' technologies, the timelines for bringing such products to market
the availability of funding sources for continued development of such products
and other statements that are not historical facts, including statements
may be preceded by the words "intends," "may," "will," "plans," "expects,"
"anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes,"
"potential" or similar words. For such statements, Nephros claims the protection
of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to various
and unknown risks and uncertainties, many of which are beyond the control
Nephros. Actual results may differ materially from the expectations contained
the forward-looking statements. Forward-looking statements are not guarantees
future performance, are based on certain assumptions and are subject to various
known and unknown risks and uncertainties, many of which are beyond the control
of Nephros. Actual results may differ materially from the
expectations contained in the forward-looking statements.
that may cause such differences include the risks that: (i) products
that appeared promising to Nephros in research or clinical trials may not
demonstrate anticipated efficacy, safety or cost savings in subsequent
pre-clinical or clinical trials; (ii) Nephros may not obtain appropriate
necessary governmental approvals to achieve its business plan or effectively
market its products; (iii) product orders may be cancelled, patients currently
using Nephros's products may cease to do so and patients expected to begin using
Nephros's products may not; (iv) Nephros's technology and products may not be
accepted in current or future target markets, which could lead to the failure
achieve market penetration of Nephros's products; (v) Nephros may not be able to
sell its ESRD or water filtration products at competitive prices or profitably;
(vi) Nephros may not be able to satisfy its debt obligations when they become
due and payable and meet its anticipated cash needs and may not be successful
obtaining additional funding in order to continue operations or fund its
clinical trials; (vii) Nephros may not be able to build key relationships
physicians, clinical groups and government agencies, pursue or increase sales
opportunities in Europe or elsewhere, or be the first to introduce
hemodiafiltration therapy in the United States; (viii) Nephros may not be
to secure or enforce adequate legal protection, including patent protection,
its products; and (ix) Nephros may be unable to show progress consistent
its plan of compliance to meet the American Stock Exchange's continued listing
standards or may be otherwise unable to timely regain compliance with the
listing standards. More detailed information about Nephros and the
risk factors that may affect the realization of forward-looking statements
set forth in Nephros's filings with the Securities and Exchange Commission,
including Nephros's Annual Report on Form 10-KSB filed with the SEC for the
fiscal year ended December 31, 2006 and Nephros's Quarterly Report filed on Form
10-QSB filed with the SEC for the quarter ended March 31,
2007. Investors and security holders are urged to read those
documents free of charge on the SEC's web site at
www.sec.gov. Nephros does not undertake to publicly update or revise
its forward-looking statements as a result of new information, future events
technology with key and marketable advantages in both the blood and water
Demonstrated Product Efficacy
User-friendly product designs responding to critical market needs and offering
unique, measurable performance advantages
Favorable Market Pricing
An Enhanced Quality of Life
and Development Progress
happened since year-end?
happened since year-end?
forces are driving to adoption of more effective therapies, and HDF in
GAO Report issued in November 2006 calls for bundling of Dialysis therapy
drug expenses. This provides a driver toward improved ESRD therapies to reduce
medication requirements.
forces are driving to adoption of more effective therapies, and HDF in
November 2006, a series of reports in The New York Times, The Wall
Street Journal, MarketWatch, and other publications in the U.S.
and abroad are calling into question the safety of Epoiten (anemia medication)
in dosages commonly applied in the U.S. According to these
forces are driving to adoption of more effective therapies, and HDF in
population growth is currently averaging 6% per year in the U.S.; a demonstrated
35% reduction in mortality risk with HDF can dramatically accelerate
growth of the clinical "customer base":
Strategy: ESRD Therapy
Forces on Water Quality
DSU end-point filtration is the clear solution in reducing infection and
providing a safe water environment
Strategy: Water Filtration